Aferrix is an innovative leader in development and applications of novel tools for early diagnosis and monitoring of toxic iron in the serum. The company has developed several methods that quantify different forms of toxic iron in the serum, which are not detected by conventional tests. Aferrix offers iron testing services and kits for research and treatment centers that specialize in iron over load diseases (Thalassemia, Hemochromatosis, Myelodysplastic syndrome) and to pharmaceutical companies that are developing iron chelators. The company was founded by Prof. Zvi Ioav Cabantchik, Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel.

Our groundbreaking carbon capture technology efficiently deals with high concentrations of carbon dioxide, and simultaneously allows a circular economy. By transforming carbon dioxide into valuable industrial minerals and products that can be used across a wide range of industries, Airovation presents an economically viable answer to one of the greatest challenges that humanity is facing.

​

Worldwide, head and neck cancers are the sixth leading cancer group by incidence, with approximately 630,000 new patients diagnosed annually, resulting in more than 350,000 deaths every year. Oral cancer is one of the most common types of tumors in the head and neck, while squamous cell carcinomas (SCCs) constitute more than 90% of all oral cancer. Oral SCCs are invasive lesions with a significant recurrence rate that frequently metastasize, where tongue tumors have the greatest tendency of all oral SCCs for metastasis to the neck.

Amenity Analytics develops cloud-based analytics tools to help businesses draw actionable insights from text on a massive scale. With domain-expertise in the Financial sector, Amenity’s products transform unstructured data into targeted information and deliver it in elegant formats that are intuitive to use, frictionless to onboard, and designed to complement existing workflows.

Ananda Labs is reversing aging-related conditions through epigenetic reprogramming. Our mission is to develop treatments that reverse aging-related diseases, rejuvenate appearance for a younger look, and improve the function of the immune system as preventive medicine.

APIX Biosciences has been established by two of the worlds’ leading authorities on bee nutrition who seek to commercialize their work, and that of an international research team involving The Hebrew University of Jerusalem (Israel) and the Universities of Oxford and Newcastle (UK) that, after 7+ years’ work, has resulted in a new feed formulation for honeybees that is demonstrably superior to any of those presently on the market.

Innovative feed additives result in larger, meatier fish. AquiNovo’s non-GMO and non-hormonal feed additives result in significant improvement in both growth and Feed Conversion Ratio (FCR). The same quantity of feed is thereby converted into more biomass. Size distribution also improves, providing farmers with more larger fish and less smaller fish.

Ayana Pharma develops liposome-based treatments for cancer. Ayana was formed to leverage the benefits of the anticancer drug Doxil, an FDA-approved liposomal nanodrug that has been used in the treatment of ovarian cancer, metastatic breast cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. Co-founded by one of Doxil’s co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions. Ayana has completed fundraising to support an abbreviated new drug application (ANDA), filing, and commercialization.

BacoCure is developing a novel bacterial product for local therapy (intravesicular) of patients with non-muscle invasive bladder cancer. BacoCure’s lead product is a novel mutated and inactivated uropathogenic bacteria that has demonstrated impressive anti-tumor effects via a novel and differentiated mechanism of action with a better safety profile compared to Bacillus Calmette-Guerin. The product is at an advanced preclinical development stage.

Founded in 2018, Believer (formerly Future Meat Technologies) is a food-tech company that’s developing a distributive platform for the cost-efficient, non-GMO production of meat directly from animal cells, without the need to raise or harvest animals. Future Meat Technologies products are delicious, healthy and safe offering a vision of sustainable cost-effective agriculture to meet the protein demands of future generations. The technology is based on the award-winning work of Prof. Yaakov Nahmias at the Hebrew University of Jerusalem.